To the Editor: We appreciate the interest in our work and the thoughtful comments made by Dr. Kripke and his colleagues. We agree that in establishing a priori criteria for study inclusion we "set the bar" a bit higher than in their Cochrane review. We believe our study inclusion criteria, as described in the article, are reasonable and consistent with conventional standards for clinical trial study design (1). Also, in contrast to the Cochrane review, we focused on a more homogeneous diagnostic group (e.g., we did not include studies of subsyndromal depression, schizoaffective disorder, or bipolar disorder) and age range. In addition, we set parameters for a minimum therapeutic dose of active treatment, as well as a maximum amount for placebo conditions.